Adirondack Trust Co. Has $1.48 Million Stake in Pfizer Inc. (NYSE:PFE)

Adirondack Trust Co. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 3.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,621 shares of the biopharmaceutical company’s stock after selling 1,714 shares during the period. Adirondack Trust Co.’s holdings in Pfizer were worth $1,477,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Newbridge Financial Services Group Inc. raised its position in shares of Pfizer by 19.1% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 17,275 shares of the biopharmaceutical company’s stock valued at $497,000 after buying an additional 2,769 shares during the last quarter. HighPoint Advisor Group LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $5,135,000. Fairman Group LLC bought a new stake in Pfizer in the fourth quarter valued at about $84,000. Napatree Capital LLC bought a new stake in Pfizer in the fourth quarter valued at about $729,000. Finally, Livelsberger Financial Advisory bought a new stake in Pfizer in the fourth quarter valued at about $118,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock traded up $0.36 during trading hours on Tuesday, reaching $27.34. 8,496,546 shares of the company were exchanged, compared to its average volume of 41,143,277. The stock’s fifty day moving average is $27.57 and its two-hundred day moving average is $27.74. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $39.87. The company has a market cap of $154.92 billion, a price-to-earnings ratio of -455.26, a P/E/G ratio of 1.08 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period in the prior year, the business posted $1.23 earnings per share. Pfizer’s revenue was down 19.5% compared to the same quarter last year. Sell-side analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were issued a $0.42 dividend. The ex-dividend date was Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.14%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PFE. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday. Finally, Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.